On March 9, 2025, Fortress Biotech's subsidiary Checkpoint Therapeutics entered into a merger agreement with Sun Pharmaceutical, where Checkpoint shareholders will receive $4.10 in cash and a contingent value right worth up to $0.70 based on future m
AI Assistant
FORTRESS BIOTECH INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.